Andreas Argyrides
Stock Analyst at Oppenheimer
(4.30)
# 1,312
Out of 4,361 analysts
390
Total ratings
44.6%
Success rate
9.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Reiterated: Buy | $40 | $17.24 | +132.02% | 9 | May 21, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $3.93 | +103.56% | 19 | May 15, 2026 | |
| UTHR United Therapeutics | Rated: Hold | n/a | $540.05 | - | 19 | May 11, 2026 | |
| LRMR Larimar Therapeutics | Rated: Hold | n/a | $3.30 | - | 8 | May 11, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $10.58 | - | 3 | May 11, 2026 | |
| LQDA Liquidia | Rated: Hold | n/a | $55.11 | - | 17 | May 11, 2026 | |
| GOSS Gossamer Bio | Rated: Hold | n/a | $0.2002 | - | 19 | May 11, 2026 | |
| MNPR Monopar Therapeutics | Rated: Hold | n/a | $60.99 | - | 4 | May 11, 2026 | |
| KROS Keros Therapeutics | Rated: Hold | n/a | $10.55 | - | 17 | May 11, 2026 | |
| MLTX MoonLake Immunotherapeutics | Rated: Hold | n/a | $17.87 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.90 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.43 | - | 8 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $11 | $5.25 | +109.52% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $5 | $2.17 | +130.41% | 4 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $98 | $57.33 | +70.94% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $3.99 | +150.63% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $30.91 | +100.58% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $19.82 | +111.91% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.47 | +512.24% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $16.25 | +127.69% | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $2.39 | +31,280.75% | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8577 | - | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.025 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $11.00 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $75 | $0.3402 | n/a | 18 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $105 | $17.75 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.214 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $12.29 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $6.52 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $22.25 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $53.32 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $14.64 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $216.60 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8005 | n/a | 6 | Aug 25, 2022 |
Dyne Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $40
Current: $17.24
Upside: +132.02%
Aquestive Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: $8
Current: $3.93
Upside: +103.56%
United Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $540.05
Upside: -
Larimar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $3.30
Upside: -
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.58
Upside: -
Liquidia
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $55.11
Upside: -
Gossamer Bio
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $0.2002
Upside: -
Monopar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $60.99
Upside: -
Keros Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.55
Upside: -
MoonLake Immunotherapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $17.87
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $8.90
Upside: -
Apr 27, 2026
Rated: Hold
Price Target: n/a
Current: $3.43
Upside: -
Apr 24, 2026
Maintained: Buy
Price Target: $9 → $11
Current: $5.25
Upside: +109.52%
Apr 24, 2026
Maintained: Buy
Price Target: $7 → $5
Current: $2.17
Upside: +130.41%
Apr 24, 2026
Maintained: Buy
Price Target: $105 → $98
Current: $57.33
Upside: +70.94%
Mar 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $3.99
Upside: +150.63%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $30.91
Upside: +100.58%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $19.82
Upside: +111.91%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $1.47
Upside: +512.24%
Oct 9, 2025
Maintained: Buy
Price Target: $37
Current: $16.25
Upside: +127.69%
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $2.39
Upside: +31,280.75%
Jul 17, 2025
Rated: Hold
Price Target: n/a
Current: $0.8577
Upside: -
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.025
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $11.00
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $5 → $75
Current: $0.3402
Upside: n/a
Aug 13, 2024
Maintained: Hold
Price Target: $105
Current: $17.75
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.214
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $12.29
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $6.52
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $22.25
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $53.32
Upside: n/a
Feb 22, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $14.64
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $216.60
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $0.8005
Upside: n/a